Vancouver, British Columbia – July 02, 2020 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFD) (“NOVA” or the “Company”) is pleased to announce that Dr. Aylia Mohammadi has joined the Company’s Board of Directors.
Dr. Aylia Mohammadi (BSc, MSc, PhD) is an experienced scientist with research expertise in both basic science and clinical translation. She is a TEDx speaker and has received awards for her work presented at national and international conferences. Dr. Mohammadi obtained her PhD in Biological Physics from the Donnelly Centre for Cellular & Biomolecular Research, and subsequently completed a postdoctoral fellowship at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto. Her graduate training was inherently multidisciplinary, integrating techniques in molecular biology, neuroscience, and genetics. For her postdoctoral research, she examined underlying molecular mechanisms of inflammatory bowel disease, giving her a strong and relevant background to guide NOVA’s scientific aims.
As President and Chief Scientific Officer of Nova Mentis Biotech Corp., Dr. Aylia Mohammadi will spearhead and oversee all research and development initiatives driven by the company, focused on investigating the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes.
“We are excited and fortunate to have Dr. Aylia Mohammadi join the Board. This is a strategic and important appointment coming off the recent acquisition of Nova Mentis Biotech Corp.,” said William Rascan, President and CEO of NOVA.
As NOVA (formerly Liberty Leaf) is deemed to be a key investor of a Standard Licensed cannabis facility in Just Kush, Dr. Aylia Mohammadi’s appointment to NOVA’s Board is subject to successfully obtaining the required Health Canada Security Clearance.
About Nova Mentis Life Science Corp.
Nova Mentis Life Science Corp. (formerly Liberty Leaf Holdings Ltd.) is a Canadian-based, public company whose focus is to build and support a diversified portfolio of health and wellness businesses. Key holdings include its wholly-owned subsidiary, Nova Mentis Biotech Corp., a R&D driven company focused on exploring the anti-inflammatory effects of psilocybin in underexplored metabolic indications such as obesity and diabetes – Just Kush Enterprises, a Health Canada Standard Licensed facility focused on the cultivation of AAAA premium, small batch, terpene rich Kush dominant cultivars cured to perfection.
On Behalf of the Board
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
Toll Free: 1-833-542-5323
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Liberty Leaf’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.